Astra invests US$ 2 bn in US R&D; key AbbVie asset from US$ 8.7 bn Cerevel buy flunks phase 2 trials
This week’s Phispers is packed with news about deals. First, AstraZeneca announced a US$ 2 billion investment in the...
Impressions : 1088
Novo’s parent buys Catalent for US$ 16.5 bn, Lilly calls for scrutiny; Novartis acquires MorphoSys
The Novo Nordisk-Eli Lilly rivalry over obesity drugs got intensified with Novo Nordisk’s parent company acquiring contra...
Impressions : 1518
Pfizer’s oral Covid drug bags authorization in US; Biogen slashes price of its Alzheimer’s drug by half
In this week’s Phispers, we bring you updates on Biogen’s controversial Alzheimer’s drug, Novartis’ pla...
Impressions : 1887
Pfizer’s Covid-19 pill retains 89 percent efficacy, works on Omicron; CSL buys Vifor for US$ 11.7 billion
In
this week’s Phispers, we bring you news on several M&As and tie-ups along with updates on Covid-19 medications an...
Impressions : 1661
Three-shot course of Pfizer jab neutralizes Omicron; AbbVie, Pfizer, Lilly drugs hit by FDA’s strict safety warnings
In
this week's
Phispers, we bring you more news on Covid vaccines, mergers and acquisitions,
regulatory updates, and account...
Impressions : 2307
White House unveils plans to roll out jabs for 5 to 11 year olds; FDA authorizes Moderna, J&J boosters
This week, Phispers has more updates on Covid vaccines and boosters. Novavax’s Covid-19 vaccine program may have hit a br...
Impressions : 1748
MI5 says Russian spies stole design of Astra-Oxford jab; Sanofi, GSK, Pfizer, BI can’t escape Zantac lawsuits
This week, we bring you news from the UK, where security services have alleged that Russian spies stole the blueprint of AstraZ...
Impressions : 2152
Pfizer unveils new brand identity; EMA, FDA signal delay in conditional nod to AstraZeneca’s vaccine
The New Year opened with ample news from the world of pharmaceuticals.
Drug behemoth Pfizer unveiled a new brand identity whi...
Impressions : 1881
2020 begins with drug price increases in US and mysterious illness in China
This week in Phispers, we have news about pharmaceutical companies ushering in the new year with a hike in US list prices of ov...
Impressions : 2771
Big pharma slash prices for China’s insurance scheme; plan major investments in gene therapy
This week, Phispers brings you news on 11 large multinational drugmakers, including Pfizer and Novartis, that have set aside US...
Impressions : 2179
New book on quality issues in generic drugs sends FDA in damage control mode; 21 generic firms sued over price-fixing
This week, Phispers is loaded with news from the US.
First, a coalition of 44 states sued Teva and 20 other generic companies...
Impressions : 4099
Insys founder Kapoor convicted in opioid scandal; FDA rules changing due to new technologies
This week, Phispers brings you news about John Kapoor, the founder of Insys who was found guilty of engaging in a bribery schem...
Impressions : 3737
Top drugs and pharmaceutical companies of 2018 by revenues
The drug pricing debate continued to dominate news headlines in 2018, and many companies were in the news for lowering drug pri...
Impressions : 35111
Aurobindo’s sartan banned in Europe; Dr. Reddy’s cost optimization drive continues, sells off another site
This week, Phispers brings you news from Dr. Reddy’s Laboratories in India which is divesting its API plant in Hyderabad ...
Impressions : 3872
High-level exit at Dr. Reddy’s; Drug stockpiling starts as firms face ‘no-deal Brexit’ blues
With Britain preparing for a ‘no-deal Brexit’, Phispers this week looks at how pharmaceutical companies are ex...
Impressions : 3396
Global drug sales to hit US$ 1.2 trillion by 2024; Gates launches biotech startup
This week in Phispers, we bring you the world drug forecasts and trends from Evaluate Pharma. There is news from Novo Nordisk a...
Impressions : 3296
PhRMA publishes list of US cancer drug pipeline; Biocon-Mylan’s Neulasta biosim bags FDA nod
This week in Phispers, Biocon–Mylan scored a big win by getting the FDA nod for its biosimilar to Amgen’s Neulasta....
Impressions : 2473
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.